Pfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their immunotherapy Bavencio produces a survival benefit in bladder cancer, when used as a maintena
The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead
